» Articles » PMID: 38512653

Unmet Needs of Drugs for Irritable Bowel Syndrome and Inflammatory Bowel Diseases: Interest of Vagus Nerve Stimulation and Hypnosis

Overview
Specialty Pharmacology
Date 2024 Mar 21
PMID 38512653
Authors
Affiliations
Soon will be listed here.
Abstract

The gut and the brain communicate bidirectionally through the autonomic nervous system. The vagus nerve is a key component of this gut-brain axis, and has numerous properties such as anti-inflammatory, antinociceptive, anti-depressive effects. A perturbation of this gut-brain communication is involved in the pathogeny of functional digestive disorders, such as irritable bowel syndrome, and inflammatory bowel diseases. Stress plays a role in the pathogeny of these diseases, which are biopsychosocial models. There are presently unmet needs of pharmacological treatments of these chronic debilitating diseases. Treatments are not devoid of side effects, cost-effective, do not cure the diseases, can lose effects over time, thus explaining the poor satisfaction of patients, their lack of compliance, and their interest for non-drug therapies. The gut-brain axis can be targeted for therapeutic purposes in irritable bowel syndrome and inflammatory bowel disease through non-drug therapies, such as hypnosis and vagus nerve stimulation, opening up possibilities for responding to patient expectations.

Citing Articles

Irritable Bowel Syndrome: A Hallmark of Psychological Distress in Women?.

Marano G, Traversi G, Pola R, Gasbarrini A, Gaetani E, Mazza M Life (Basel). 2025; 15(2).

PMID: 40003686 PMC: 11856493. DOI: 10.3390/life15020277.


Non-invasive vagus nerve stimulation in anti-inflammatory therapy: mechanistic insights and future perspectives.

Liu F, Wu J, Gong L, Yang H, Chen H Front Neurosci. 2024; 18:1490300.

PMID: 39605787 PMC: 11599236. DOI: 10.3389/fnins.2024.1490300.


Role of stress and early-life stress in the pathogeny of inflammatory bowel disease.

Bonaz B, Sinniger V, Pellissier S Front Neurosci. 2024; 18:1458918.

PMID: 39319312 PMC: 11420137. DOI: 10.3389/fnins.2024.1458918.

References
1.
Ben-Horin S, Chowers Y . Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011; 33(9):987-95. DOI: 10.1111/j.1365-2036.2011.04612.x. View

2.
Black C, Yuan Y, Selinger C, Camilleri M, Quigley E, Moayyedi P . Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2019; 5(2):117-131. DOI: 10.1016/S2468-1253(19)30324-3. View

3.
Black C, Thakur E, Houghton L, Quigley E, Moayyedi P, Ford A . Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2020; 69(8):1441-1451. DOI: 10.1136/gutjnl-2020-321191. View

4.
Bonaz B . Anti-inflammatory effects of vagal nerve stimulation with a special attention to intestinal barrier dysfunction. Neurogastroenterol Motil. 2022; 34(10):e14456. PMC: 9787579. DOI: 10.1111/nmo.14456. View

5.
Bonaz B, Bernstein C . Brain-gut interactions in inflammatory bowel disease. Gastroenterology. 2012; 144(1):36-49. DOI: 10.1053/j.gastro.2012.10.003. View